Thailand Medical News - For All The Latest Breaking Medical News, Health News, Research News, COVID-19 News, Outbreak News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Heart And Cardiology News, Epigenetic News, Cancer News,

Nikhil Prasad  Fact checked by:Thailand Medical News Team Jan 18, 2024  1 month, 3 days, 8 hours, 23 minutes ago

COVID-19 News: Clinical Trial Shows That Omega-3 Fatty Acid Supplementation Improves Metabolic And Inflammatory Profiles Of Hospitalized COVID-19 Patients

facebook sharing button Share
twitter sharing button Tweet
linkedin sharing button Share
COVID-19 News: Clinical Trial Shows That Omega-3 Fatty Acid Supplementation Improves Metabolic And Inflammatory Profiles Of Hospitalized COVID-19 Patients
Nikhil Prasad  Fact checked by:Thailand Medical News Team Jan 18, 2024  1 month, 3 days, 8 hours, 23 minutes ago
COVID-19 News: As the global scientific community races to uncover effective treatments for COVID-19, a groundbreaking study has emerged from the collaborative efforts of institutions such as the Escuela Superior de Medicina del Instituto Politécnico Nacional-Mexico, Universidad La Salle-México, Universidad Tecnológica de Nezahualcóyotl-Mexico, and Hospital Regional de Alta Especialidad de Ixtapaluca-Mexico. This study covered in this COVID-19 News report, delves into the impact of Omega-3 Fatty Acid (O3FA) supplementation on the metabolic and inflammatory profiles of Mexican adults hospitalized with COVID-19, providing promising insights into a potential therapeutic avenue.

Omega-3 supplements can prevent COVID-19 disease severity
Previous coverages by Thailand Medical News had also showed that Omega 3 Fish Oil Supplements not only helps prevent COVID-19 disease severity but also helps with COVID-19 induced cardiovascular issues.
The Interplay Between Nutrition, COVID-19, and Comorbidities
The severity of COVID-19 has been intricately linked to preexisting comorbidities and the nutritional status of individuals. Malnutrition, often characterized by elevated cytokine levels in the later stages of the disease, has emerged as a critical factor influencing both infection susceptibility and disease progression. Recognizing the pivotal role of optimal nutrition in immune system function, researchers have turned their attention to omega-3 fatty acids (O3FAs), known for their anti-inflammatory properties, as potential agents to reduce morbidity and mortality in COVID-19 patients.
Study Design and Implementation
This randomized, double-blind clinical trial sought to assess the impact of O3FA supplementation in unvaccinated Mexican patients hospitalized with COVID-19. The study design involved administering O3FAs for a duration of two weeks, beginning within the firs t two hours of hospitalization. The dosage, set at one capsule of 1.4 g O3FAs daily, aimed to meet human physiological requirements efficiently.
Study Findings
The comprehensive evaluation of the intervention revealed a multi-systemic modulatory influence on inflammatory and metabolic pathways, manifesting in significant improvements in various biomarkers.
Omega-3 fatty acid (O3FA) supplementation demonstrated notable effects on various health markers. Leukocyte counts, particularly neutrophils, and hematocrit levels showed significant reduction post-O3FA supplementation, suggesting a modulatory effect on neutrophil function and a more homogenized inflammatory response. Metabolism markers exhibited nuanced changes, with an increase in high-density lipoprotein (HDL) cholesterol, leading to improved total cholesterol/HDL and LDL/HDL ratios. Low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) cholesterol levels decreased, especially in individuals with elevated baseline VLDL and LDL levels, along with a noteworthy decline in triglyceride levels. Glucose, creatinine, and BUN levels also decreased, indicating broader metabolic modulation.
Elevated LDL/HDL and total cholesterol/HDL ratios, conventionally associated with cardiovascular risks in severe COVID-19 outcomes, significantly decreased. Liver enzymes, such as GPT, GOT, and alkaline phosphatase, displayed variable changes, suggesting a complex influence on these enzymes. Bilirubin levels showed reduced variability, highlighting stabilization in hepatic excretory function. Notably, the study revealed a significant reduction in lactate dehydrogenase (LDH), a marker of cellular damage in severe COVID-19 cases, post-O3FA administration. The asymmetric distribution in LDH reduction implies a non-linear dose–response relationship, suggesting potential efficacy in specific subpopulations or advanced disease stages. Overall, the findings suggest O3FA supplementation's systemic modulation of inflammatory and coagulative responses, potentially through inhibiting pro-inflammatory eicosanoids and altering inflammation-related gene expression profiles.
Unraveling the Biological Mechanisms
Understanding the intricate biochemical mechanisms through which O3FAs exert their effects becomes imperative in appreciating the potential therapeutic impact on COVID-19. The viral infection induces a "cytokine storm," characterized by an overactive immune response. O3FAs have demonstrated the ability to downregulate this inflammatory response, reducing viral entry, and enhancing antiviral responses. Notably, the reduction in neutrophil infiltration, pro-inflammatory mediators, and the improvement in macrophage function underscore the immunomodulatory effects of O3FAs on viral infections and tissue damage.
Clinical Implications of O3FA Supplementation
Severe cases of COVID-19 are often associated with hyperinflammation, and the study findings suggest that O3FA supplementation may play a crucial role in mitigating this inflammation by regulating metabolism and limiting inflammatory responses. The observed impact on inflammatory markers, lipid profiles, and hepatic parameters implies potential benefits in attenuating cardiovascular risk profiles and expediting patient recovery. Furthermore, the reduction in glucose, creatinine, and BUN levels indicates a broader metabolic modulation, suggesting potential benefits beyond the immune response.
Discussion on Study Limitations
While the study provides valuable insights, acknowledging its limitations is crucial for a comprehensive understanding. The sample size and the relatively short duration of the trial, along with the lack of standardized medical treatment, prompt considerations for further research. Future studies should explore the dose–response relationship of O3FA supplementation and consider a multicentric approach to enhance diversity in measured variables.
Implications for Future Research and Treatment Strategies
The study's findings offer a compelling rationale for further exploration of O3FA supplementation as a potential therapeutic intervention for COVID-19. Rigorous methodologies, including randomized controlled trials and multi-omics analyses, are imperative to unravel the underlying biochemical and biomolecular mechanisms. Such endeavors could pave the way for targeted therapeutic interventions and personalized medicine approaches in managing not only COVID-19 but also its complications and other inflammatory diseases.
Expanding on Biological Mechanisms
Delving deeper into the immunomodulatory effects of O3FAs, the study sheds light on their potential to downregulate the NLRP3 inflammasome, a cytosolic complex pivotal in initiating the inflammatory cascade. By inhibiting the synthesis of pro-inflammatory eicosanoids, altering gene expression related to inflammatory mediators, and modifying cell membrane characteristics, O3FAs may mitigate the cytokine storm frequently observed in severe COVID-19 cases. The modulation of Toll-like receptor (TLR) signaling pathways, integral to innate immunity, adds another layer to the intricate mechanisms at play.
Clinical Implications and Metabolic Modulation
The observed improvements in lipid profiles and liver function tests suggest that O3FAs may exert a synergistic effect, not only modulating inflammatory responses but also influencing key metabolic indexes. The increase in high-density lipoprotein (HDL) cholesterol, coupled with reductions in low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) cholesterol levels, indicates potential cardio-protective effects. These lipidomic realignments contribute to an overall improvement in the patient's clinical status, presenting a promising avenue for managing COVID-19 complications.
Implications for Patient Recovery
The study findings raise the possibility of expedited patient recovery and reduced morbidity, particularly in terms of thromboembolic events and acute respiratory distress syndrome (ARDS). The potential antithrombotic properties suggested by the negative skewness in lymphocyte and platelet counts post-supplementation highlight the multifaceted nature of O3FA effects on the immune and coagulation systems.
Conclusions and Future Directions
In conclusion, the clinical trial assessing O3FA supplementation in Mexican adults hospitalized with COVID-19 not only provides valuable insights into its potential benefits but also opens new avenues for therapeutic interventions. The immunomodulatory and metabolic effects observed underscore the importance of exploring innovative approaches to enhance patient outcomes in the face of the ongoing COVID-19 pandemic. As research in this field advances, future studies employing advanced analytical techniques and rigorous methodologies will be essential to unravel the molecular mechanisms and pave the way for targeted therapeutic interventions and personalized medicine approaches.
The study findings were published in the peer reviewed journal: Diseases.
For the latest COVID-19 News, keep on logging to Thailand Medical News.
Read Also:


Jun 10, 2023  9 months ago
COVID-19 News - DNA Methylation - Asymptomatic SARS-CoV-2 Infections
Sep 08, 2022  1 year ago
Source- Medical News - COVID-19 Research - Impaired Pain Modulation
Aug 04, 2022  2 years ago
Source: Medical News - SARS-CoV-2 & Cancer
Aug 13, 2020  4 years ago
Source: Supplements For COVID-19